On January 20, 2018, Zhejiang Jianfeng Group Co., Ltd. (Stock Code: 600668) announced that its holding subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd. and Biocompounds Pharmaceutical Inc. signed the agreement on capital increase and share transfer of Biocompounds Pharmaceutical Inc. It is proposed to invest 111.3279 million yuan in Biocompounds Pharmaceutical Inc. by means of share acquisition and capital increase. After the completion of the investment, Jianfeng pharmaceutical will hold 55% of the shares of Biocompounds Pharmaceutical Inc., and will establish the R & D and production base of API and intermediates based on Biocompounds Pharmaceutical Inc. and its subsidiaries. Biocompounds Pharmaceutical Inc. will realize the leap from a technology R & D enterprise to an industrial high-end manufacturing platform.
Biocompounds pharmaceutical Inc., founded in 2003, is an innovative company committed to the licensed production of high-end generic drugs and customized research and development of new drugs for major pharmaceutical manufacturers at home and abroad. It is a high-tech enterprise in Shanghai, a "specialized and special new" science and technology enterprise in Shanghai and a "patent pilot enterprise in Shanghai". It has built an academician expert workstation and an "enterprise technology center" in Songjiang District. It has a number of achievements of "Shanghai high-tech achievement transformation project", and has won the "second prize of scientific and technological progress in Songjiang District of Shanghai", ect.
Biocompounds Pharmaceutical Inc. has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as Changtai chemical) and Anhui Biocompounds Chemicals Co., Ltd. (hereinafter referred to as Anhui Biocompounds Chemicals). Changtai chemical is a pesticide manufacturer designated by the Ministry of industry and information technology. It is a wholly-owned subsidiary acquired by Biocompounds Pharmaceutical Inc. through acquisition. It was established in July 2007 with a registered capital of 30 million yuan and covers an area of 78351.51 square meters. Now it has three chemical synthesis workshops and one pesticide preparation compounding workshop. After the entry of Biocompounds Pharmaceutical Inc., Changtai Chemical has further improved its supporting capacity in storage, power distribution, steam supply, safety and environmental protection, and will further extend to pharmaceutical intermediates. Anhui Biocompounds Chemicals was founded in December 2016 with a registered capital of 10 million yuan. In 2017, it was approved to undertake the major emerging industry engineering project "small molecule targeted drug manufacturing base" in Anhui Province. It will be built into a production base focusing on pharmaceutical raw materials to undertake the transformation of achievements of Biocompounds Pharmaceutical.
Based on the concept of complementary advantages and win-win cooperation, this cooperation is an important measure combined with the strategic policy of Jianfeng group's "cooperation and innovation to strengthen the main business and standardize science for development" and the strategic goal of BPI "comprehensive supply platform for small molecule targeted drug initial raw materials and advanced intermediates of precision medicine". Take BPI and its subsidiaries as the platform to establish the R & D and production base of API and intermediates, which is specifically reflected in focusing on building three plates. First, increase investment in BPI Shanghai R & D center. The second is to establish a high-end technological innovation and manufacturing base of APIs and intermediates on the platform of subsidiaries. Third, build a CDMO development and customization platform for new drugs and intermediates.
This cooperation will further build BPI into a supplier with small molecule targeted drug starting materials, advanced intermediates to API R & D and manufacturing base by combining the strong financial advantages of listed companies, comprehensive advantages in medicine and big health industry and BPI's solid R & D and technical foundation. Further extend and improve the industrial chain of Jianfeng pharmaceutical's business, improve the R & D capacity of Jianfeng pharmaceutical, strengthen the production guarantee of API of Jianfeng pharmaceutical, and improve the comprehensive strength and industry status of Jianfeng pharmaceutical.
Brief introduction to Jianfeng pharmaceutical
Zhejiang Jianfeng Pharmaceutical Co., Ltd., established in December 1998 with a registered capital of 198.53 million yuan, is a holding subsidiary of the listed company Zhejiang Jianfeng Group Co., Ltd. (Stock Code: 600668).
Jianfeng pharmaceutical has eight subsidiaries engaged in pharmaceutical business, involving pharmaceutical industry, commerce, scientific research and other fields. With Academician expert workstation and post doctoral mobile station, it is a national top 100 pharmaceutical enterprises, top 10 pharmaceutical enterprises in Zhejiang Province, national key high-tech enterprises, national high-tech industrialization demonstration project enterprises, innovative demonstration enterprises in Zhejiang Province and AAA "contract abiding and trustworthy" units in Zhejiang Province.
The company's existing products are mainly anti-infective drugs, cardiovascular drugs and antidepressant drugs. The main varieties include amlodipine aspartate tablets, aceclofenac sustained-release tablets, paroxetine hydrochloride tablets, cefuroxime hydrochloride for injection, penciclovir for injection, sodium hyaluronate eye drops, etc.
The company pursues the business philosophy of "science and technology creates health" and adheres to the development of high-tech and high value-added chemical raw materials and new chemical pharmaceutical preparations, supplemented by natural product extraction and Chinese patent medicine preparations. Jianfeng pharmaceutical has established a "4 + 2" new product R & D strategy, focusing on four main product lines: anti-infective drugs, cardiovascular and cerebrovascular drugs, drugs for elderly children and anti-tumor drugs. With first-class business philosophy and first-class production management, the company will create first-class products, cast a famous brand trusted by the public and achieve human health!
Everything begins to grow in spring..
In the colorful fireworks and cheerful music, the new year is coming to us.过In the past year, because of your support and cooperation, BPI has grown. In the new year, we will face new challenges and opportunities.
On the occasion of the arrival of the Spring Festival, BPI sincerely expresses its deep gratitude to all BPI employees for their efforts and hard work, to our visionary investors, to sincere and trusted suppliers and customers at home and abroad, and to our partners who care, help and warmly support us. We wish you a happy Spring Festival! To be harmony, healthy and lucky in the new year!
Biocompounds Pharmaceutical Inc.
